1,4-Bis(4-bromophenyl)buta-1,3-diyne, 95+%, 100mg

3-Aminosalicylic Acid>98.0%(HPLC)5g

2,2'-((6-Chloro-2,4-dioxopyrimidine-1,3(2H,4H)-diyl)bis(methylene))dibenzonitrile, 98%, 10mg

5-(4-Fluorophenyl)-2H-pyrazol-3-ylamine, 95.0%, 5g

(S)-3-(4-Chloro-phenylsulfanyl)-pyrrolidine-1-carboxylic acid tert-butyl ester, 95.0%, 100mg

2-Chloro-4-methylnicotinamide, 95.0%, 1g

1-(5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrrolidin-2-one, 97%, 1g

Butyl 4-[(4-Methoxybenzylidene)amino]cinnamate>98.0%(T)1g

2-Bromo-4-chloro-6-fluorobenzoic acid, 97%, 10g

6-Bromo-5-(trifluoromethyl)nicotinic acid, 95.0%, 250mg

Plan PLPH S100x/1.25 phase contrast objective

3-CYANO-1H-INDOLE-6-CARBOXYLIC ACID, 95.0%, 250mg

(1r,2s)-Cyclohexane-1,2-diamine dihydrochloride, 95+%, 250mg